Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer.
Saved in:
| Title: | Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer. |
|---|---|
| Authors: | Ji Y; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. yan.ji@novartis.com., Wang C; Novartis Pharma AG, Basel, Switzerland., Combes FP; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Ho YY; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Fasching PA; University Hospital Erlangen Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany., Untch M; Interdisciplinary Breast Cancer Center, Helios Klinikum Berlin-Buch, Berlin, Germany., Zarate JP; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Crown J; St. Vincent's University Hospital, Dublin, Ireland. |
| Source: | Clinical pharmacokinetics [Clin Pharmacokinet] 2026 Jun 23. Date of Electronic Publication: 2026 Jun 23. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
